ORLANDO — In this video, Gailen D. Marshall Jr., MD, PhD, chair of allergy and immunology at University of Mississippi Medical Center, discusses the clinical development of the nanobody compound lunsekimig for atopic dermatitis treatment.
Lunsekimig (Sanofi) is an IL-13/thymic stromal lymphopoietin nanobody compound that has formerly been evaluated as a treatment for asthma, as Healio previously reported. Several posters and lectures presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting demonstrated the efficacy of lunsekimig as a treatment for

Awareness of auto-brewery syndrome is gradually increasing, but its recognition is still limited, which complicates diagnosis, according to experts.
Auto-brewery syndrome (ABS), “also known as gut fermentation syndrome, is a rare medical condition in which ethanol (alcohol) is produced endogenously in the digestive system by fermenting microorganisms, typically yeast,” Kenichi Tamama, MD, PhD, a professor of pathology at the University of Pittsburgh School of Medicine, told Healio.
ABS cases have been documented since 1952, although a report of a “similar phenomenon” was published back in 1902,

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, according to a presenter at CTAD.
“This research supports the potential for Kisunla to deliver meaningful and sustained benefits in early symptomatic Alzheimer’s disease, even after patients complete their treatment course,” Mark A. Mintun, MD, group vice president of neuroscience research and development at Eli Lilly and Co., told Healio.
The parent study of TRAILBLAZER-ALZ 2, a phase 3,

Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia in adults.
Etripamil (Cardamyst) is the first self-administered rapid-acting treatment option for paroxysmal supraventricular tachycardia (PSVT) to receive regulatory approval, according to a company press release.
Etripamil, a rapid-acting calcium channel blocker, is expected to be available in retail pharmacies in the first quarter of 2026, according to the release.
The FDA approval of etripamil was based on the

The COVID-19 vaccines developed for the 2024-2025 respiratory disease season were around 75% effective at preventing medically attended COVID-19 among children aged 9 months to 4 years, according to findings published by the CDC.
The vaccines also protected older children and adolescents, according to the researchers.
Although children have a lower risk for severe COVID-19 compared with adults, many are still hospitalized with the disease each year. Approximately 38,000 children and adolescents were hospitalized for COVID-19 between September 2023 and August 2024, Stephanie A. Irving, MHS,

Reframing women’s health care includes a greater emphasis on health span, and a closer look at ovarian aging, according to an expert.
At this year’s annual meeting for The Menopause Society, Jennifer Garrison, PhD, assistant professor in residence, cellular and molecular pharmacology at the University of California, San Francisco, delivered the keynote address, “Reframing Longevity and Extending Health Span in Women.”
Healio spoke with Garrison to learn more about longevity, reframing women’s health and more.
Healio: Why is this an important subject for you to talk about?
Garrison: I think we

Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies in people without diabetes need to be conducted, according to a speaker.
Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said it is crucial to assess the utility of CGM for people without diabetes with over-the-counter devices now available. As Healio previously reported, the FDA approved the Dexcom Stelo in March 2024 as

Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth growth vs. vehicle at 6 months without the risks of oral therapies, according to a press release.
Clascoterone 5% topical solution (Cosmo Pharmaceuticals) is an investigational treatment developed specifically for androgenetic alopecia. The drug blocks dihydrotestosterone directly at the hair-follicle receptor without systemic absorption. Clascoterone 1% cream (Winlevi, Sun Pharmaceuticals) is already approved as a topical acne treatment, with more than 1.5 million

With the expectations of friends and family to squeeze a high degree of activity and socialization into a short period of time during the holidays, individuals with bipolar disorder may find it difficult to maintain their daily routines.
Healio spoke to Roger Rivera, DNP, PMHNP, a family nurse practitioner and psychiatric–mental health nurse practitioner based in central Florida, to find out how those dealing with bipolar disorder can successfully navigate the holiday season, when feasting and socialization may be overwhelming.
Healio: How many are affected by bipolar disorder in the U.S., and

ORLANDO — In this exclusive Healio Video Perspective from the American Academy of Ophthalmology meeting, Steve R. Sarkisian Jr., MD, discusses the Leos endoscopic cyclophotocoagulation system.
Sarkisian said the Leos system (BVI) allows surgeons to perform the procedure with a clear view and minimal prep from operating room staff.
{{VIDEO}}
“It’s a single-use probe every time, and the view is amazing,” he told Healio. “It focuses all by itself. That auto-focus is a huge deal.”
The system has the potential to be adopted for use during cataract surgery as well as standalone glaucoma therapy,